HeartSciences (HSCS) to Release Quarterly Earnings on Monday

HeartSciences (NASDAQ:HSCS) is projected to release its results before the market opens on Monday, December 15th. Analysts expect HeartSciences to post earnings of ($0.90) per share for the quarter.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings results on Thursday, September 11th. The company reported ($1.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.41) by $0.83. On average, analysts expect HeartSciences to post $-10 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

HeartSciences Stock Performance

NASDAQ HSCS opened at $2.67 on Monday. HeartSciences has a one year low of $2.01 and a one year high of $6.47. The firm has a market cap of $7.08 million, a PE ratio of -0.32 and a beta of 2.57. The firm’s fifty day moving average is $3.10 and its two-hundred day moving average is $3.47.

Wall Street Analysts Forecast Growth

Several research firms have commented on HSCS. Wall Street Zen raised HeartSciences from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. Ascendiant Capital Markets lowered their price objective on shares of HeartSciences from $15.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, December 1st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.50.

Hedge Funds Weigh In On HeartSciences

A hedge fund recently bought a new stake in HeartSciences stock. Geode Capital Management LLC bought a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences at the end of the most recent quarter. Institutional investors and hedge funds own 17.24% of the company’s stock.

About HeartSciences

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.